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1. Introduction 
DNA-containing polyomavirus SV40 was isolated in 1961 from poliovaccine prepared on 
kidney cell culture of M.mulatta naturally infected with this virus. Main part of 
poliovaccines (IPV and OPV) was contaminated with SV40. From 1955 till 1963 hundred 
millions of people in USA, Russia (USSR), and in some other countries were immunized 
with contaminated SV40 Salk and Sabin vaccine and a lot of people became carriers of SV40. 
This virus was detected also in some human tumors. Epidemiological researches were not 
carried out in Russia before 2009.  By present time possibility and ways of SV40 excretion 
into environment and possibility of its horizontal spreading is established. From the 
beginning of 60s (in Russia a little bit later) vaccines were free from SV40 contamination. In 
this article the data about SV40 infection of population in Moscow, St. Petersburg, in some 
cities of the Black Sea coast of Caucasus, in Novosibirsk and in one area of Krasnoyarsk 
region are presented., Analysis of the source of SV40 people infection is performed.  
Small size DNA virus was isolated from mice in 1953. The virus was called “polyomavirus” 
SV40 (Gross, 1951; Gross, 1953). because it was able to produce multiple malignant tumors 
in newborn rodents. 
Simian SV40 was the second discovered polyomavirus. It was isolated in 1961 from 
poliovaccine propagated on M.mulatta kidney cell cultures naturally infected with SV40 as 
it was established later (Eddy et al., 1961; Sweet & Hilleman, 1960). 
SV 40 is a small DNA virus which does not have envelope; its capsid consisted of 72 
capsomers. The size of virion is 45 nm; the viral genome is represented by two-stranded 
DNA aprox. 5000 bp long. On character of the changes caused in cell cultures, the virus also 
has received the name “vacuolating virus”(Sweet & Hilleman, 1960; Butel et al., 1999).  
During next years polyomaviruses were isolated from different animals including different 
monkey species and from humans with different pathology as well (Simon,2008; Gjoerup, 
2010; Voevodin, 2009).).  
In 1957 baboon polyomavirus was discovered (Gardner et al., 1989); polyovavirus of African 
green monkeys was discovered in 1979 (zur Hausen & Giosmann, 1979), after that 
polyomaviruses of M.fascicularis and chimpanzee were discovered (but not isolated). Two 
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human polyomaviruses BKV and JCV were firstly isolated in 1971: JCV from a patient with 
Progressive multifocal leukoencephalopathy (Padgett et al., 1971), BKV from patient with 
nephropathy (Gardner et al., 1971; Padgett et al., 1971). 
Later 3 more polyomaviruses were isolated: KI, Wu from respiratory tract and MCV from 
rare malignant skin tumor – Merkel carcinoma (Feng et al., 2008) 
Among human viruses such ubiquitous viruses as JCV and BKV are widely known and are 
determined from 60 to 90% of cases in humans according to data of different authors 
(Knowles et al., 2006; Maginnis & Atwood, 2009). 
However many publications often contradictory were associated with simian polyomavirus 
SV40. The virus was unintentionally introduced into human populations together with 
poliovaccine contaminated with SV40 as it turned out later (Shah, 2007). 
The middle 50s of the last century was marked by epoch-making event – creating of 2 types 
of poliovaccines: Salk formolvaccine (IPV) and live attenuated Sabin vaccine (OPV). More 
than 100 million people were immunized in USA beginning from 1956 till 1963 using the 
above mentioned 2 types of vaccines; more than 70 million people were immunized in 
Russia (USSR) in 1960 using Sabin vaccine (Fisher, 1999. Rizzo, 1999, Peden, 2008, Drozdov, 
2005, Mironova et al., 2006). Significant amount of predominantly young people were 
immunized in different European countries (Shah & Nathanson, 1976).  
It is necessary to look back to the history of poliovaccine creation by Salk and Sabin. Both 
vaccines (Salk inactivated formolvaccine and Sabin live attenuated vaccine) were poliovirus 
propagated on M. mulatta kidney cell culture. Soon it was shown that in high percent of 
cases M.mulatta had been already infected with SV40 in natural conditions (Sweet 
&Hilleman, 1960; Lapin et al., 1965). That is why many poliovaccine lots were contaminated 
with this virus. As it was found out later Salk method of vaccine preparation did not 
provide full inactivation of the vaccine (Carbone et al., 1997). As to the Sabin vaccine – it was 
initially contaminated with polyomavirus (Peden, 2008). 
Zoonotic SV40 origin perhaps is beyond doubt but some authors advance an opinion in 
their publications about preexisting of this virus in humans (Levine, 1998; Geissler, 1985; 
Paracchini, 2005). This assumption could be supported if SV40 (or DNA sequences of this 
virus or antibodies to it) could be reliably detected in human materials obtained before mass 
poliovaccination. Some publications contain information about detection the antibodies to 
SV40 before beginning the vaccination against poliomyelitis (Geissler, 1985). It can be 
supposed that the virus could be introduced into human population from the countries of 
monkey natural habitat (Southeast Asia and India). Serological investigations revealed SV40 
infection of Zoo workers and in workers of India companies exporting monkeys and 
contacting with animals. SV40 footprints were detected in their blood (Horvath, 1965; Engels 
et al., 2004; Shah, 1966). All this testifies the possibility of contact infection humans from 
animals carriers of the virus.(citation from: Vastad, JAMA, 2002, 288, 1337-1338). However 
the quantity of people infected with SV40 greatly increased particularly after beginning of 
mass poliovaccination which testifies this supposition.   
Thus mass vaccination of millions of people with poliovaccine which made it possible to 
eradicate poliomyelitis as an epidemic disease simultaneously led to infection of people 
with simian polyomavirus SV40. 
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In 1961 as it was mentioned above USA investigators revealed contamination of 
poliovaccine with simian (M.mulatta) virus SV40.   
Serological investigation and PCR revealed antibodies to SV40 and virus DNA sequences in 
polio immunized people. To the researcher’s surprise the antibodies to SV40 were also 
detected in not vaccinated people. In connection with this fact the researchers came out with 
a suggestion that in human populations virus can spread horizontally (Knowles et al., 2006) 
It has been shown that virus can excrete into surrounding with excrements, breast milk, 
sperm, that supports the assumption about the possibility of horizontal spreading of the 
virus (David, 2001; Martini, 1996; Vastag, 2002). 
Some investigators described discovery of polyomaviruses in sewage and in sea and river 
waters which undoubtedly could be the source of horizontal spreading of infection in 
regions with high SV40 prevalence (Vastag, 2002; Bofill-Mas et al., 2009).  
Appearance of people infected with SV40 after immunization with polio vaccine caused 
anxiety of physicians due to virus ability to induce malignant tumors in laboratory rodents. 
However absence of apparent increase of tumors in polio vaccinated people reduced the 
interest to SV40 in people. A new wave of anxiety and long lasting discussions continuing 
up to now was caused by discovery of DNA sequencing of SV40 in some human tumors. As 
a result great many contradictory publications appeared describing infection of people with 
this virus, its origin, ways of spreading and possible connection with human pathology 
(Carbone, 1994, 1997,1999; De Rizzo, 1998, 2001; Arrington, 2000; Tognon, 2001; 
Lednicky,2001; Bergsagel, 1992; Vilchez, 2002; Klein, 2002; Bocchetta, 2001; Lapin & 
Chikobava, 2011; Cutrone et al., 2005; Carter et al., 2003; Hübner R. & Van Marck E.2002; 
Martini et al., 1998; Barbanti-Brodane et al., 2004).   
Some researchers considered discovery of SV40 in human blood and in tumors as artifact 
(Shah, 1976; Lopez-Rios, 2004; Manfredi, 2005; Mayall, 2003, and many others). 
Disagreement was caused mainly by high homology of SV40 with ubiquitous human 
polyomaviruses JCV and BKV and consequently with their immunologic and molecular-
biological reactivity (Testa, 1998; Lopez-Rios, 2004; Heinsohn, 2005; Shah & Nathanson, 
1976; Shah, 2007; Carter et al., 2003). Some researchers denied infection people with SV40 
and believed that discovered antibodies and DNA sequencing belong to human 
polyomaviruses JCV and BKV.  
Because M.mulatta are carriers of polyomavirus SV40 in natural conditions WHO 
recommended to replace in manufacture poliovaccines kidneys of rhesus monkeys with 
kidneys of green monkeys not containing this virus. At the same time methods of vaccine 
decontamination were improved. It is possible to assert that in the period from 1960 till 1962 
poliovaccine produced by USA, Great Britain, and some other European countries was free 
from SV40 contamination. However by that period of time hundred millions of people had 
been already immunized with contaminated SV40 vaccine in USA, Russia (USSR) and many 
other countries. In Russia (USSR) that produced vaccine for own needs and also for export to 
east European countries and countries of southeast Asia clearing vaccine from contamination 
happened some years later Chumakov et al., 1961;Chumarjvet al., 1963; Scovranek, 1961)  
Vaccine produced in east countries was contaminated with SV40 till 1978 according to data 
of USA and English researchers who investigated SV40 contamination in poliovaccine 
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samples produced in different time in different countries. Authors of the publication note 
that method of heat inactivation of the vaccine in the presence of MgCl2 inactivated SV40 
not completely (Cutrone et al., 2005). 
Epidemiological investigations carried out in different countries revealed infection of 
population with SV40. K. Leithner et al (2005) in Fig 4 of their article published a schematic 
map demonstrating data on infection of population with SV40 in European countries where 
contaminated SV40 vaccine was used and afterwards SV40 infection of population was 
revealed and also those countries where contaminated vaccine was also used but the 
population was not examined for SV40 infection. Such countries were Russia, Ukraine, 
Byelorussia, and some East European countries in which vaccination was carried out with 
OPV Sabin vaccine perhaps produced in Russia (USSR).  
 
Fig. 1. Red color designates countries where contaminated SV40 vaccine was used and SV40 
carriers were discovered (continuous coloring does not mean degree of prevalence). Shaded 
area designates countries where contaminated vaccine was also used but people were not 
tested for SV40 carriers. (Leithner 2005). See also Table 1. 
Authors of this publication prepared a Table on the basis of literary data which helps to 
understand where the source of SV40 infection was.  
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Country Rating of contamination 
of polio vaccines with 
SV40 
Vaccines, vaccination programs and 
origin of vaccines 
 
Albania 
 
 
 
 
Austria 
 
 
 
Bulgaria 
 
 
 
 
CSSR 
 
 
 
 
 
 
 
Denmark 
 
 
 
 
 
Finland 
 
 
 
 
Germany East 
 
 
 
 
 
Hungary 
 
 
 
 
 
Positive 
 
 
 
 
Negative 
 
 
 
Positive 
 
 
 
 
Positive 
 
 
 
 
 
 
 
Positive 
 
 
 
 
 
Negative 
 
 
 
 
Positive 
 
 
 
 
 
Positive 
 
 
 
 
 
Contaminated Russian vaccine (OPV) 
used since 1960 (Chumakov et al, 
1961;Chumakov et al, 1963; Shah & 
Nathanson, 1990; Levine et al, 1998). 
 
Mass vaccinations with SV40-free British 
vaccine (OPV) since winter 1961/62 
(Kundratitz, 1962; Friza, 1962) 
 
Contaminated Russian vaccine (OPV) 
used since 1960 (Chumakov et al, 1961; 
Chumakov et al, 1963; Shah & 
Nathanson, 1990; Levine et al, 1998). 
 
Since 1960: limited use of IPV, mass 
vaccinations with OPV, partly with 
contaminated Russian vaccine 
(Chumakov et al, 1961; Chumakov et al, 
1963; Shah & Nathanson, 1990; Levine et 
al, 1998; Skovranek,1961; Chron Wld 
Hlth Org, 1960) 
 
Vaccinations from 1955 with widely 
contaminated Danish vaccine (IPV), 
SV40-free from 1963 (Engels, 2003). A 
combined schedule was introduced in 
1968 (Murdin et al, 1996). 
 
Mass vaccinations since 1957 with SV40-
free Belgium vaccine (IPV) (Hirvonen, 
1999). Finland has never used OPV on a 
routine basis (Murdin et al, 1996) 
 
Contaminated Russian vaccine (OPV) 
used since 1960 (Geissler, 1983; 
Chumakov et al, 1963; Shah & Nathanson 
,1976; Prog Med Virol, 1990; Levine et 
al,1998, Belian & Rademacher, 1961). 
 
Since 1957: limited use of IPV, mass 
vaccinations with vaccines from the US, 
Canada, Hungary and Russia (also OPV) 
(Chumakov et al, 1963; Shah & 
Nathanson, 1976; Geissler, 1990; Levine 
et al, 1998) 
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Norway 
 
 
 
 
 
 
Poland 
 
 
 
 
 
 
Russia (USSR) 
 
 
 
 
 
 
 
 
Spain 
 
 
 
 
 
 
Sweden 
 
 
 
 
Turkey 
 
 
 
 
 
 
United Kingdom 
 
 
 
Positive 
 
 
 
 
 
 
Unclear 
 
 
 
 
 
 
Positive 
 
 
 
 
 
 
 
 
Unclear 
 
 
 
 
 
 
Positive 
 
 
 
 
Negative 
 
 
 
 
 
 
Positive 
Vaccinations started 1956 with Danish 
vaccine (IPV); since 1957 potentially 
contaminated U.S.vaccine (IPV) (Thu et 
al, 2006), change to OPV from 1967 to 
1979, then back to IPV from 1979 
onwards (Murdin et al, 1996). 
 
Mass vaccinations (OPV) since 1958 with 
Koprowski strain live vaccine [94]; 
vaccine was claimed to be Russian made 
(Minor et al, 2003), but Russian vaccines 
were derived from Sabin's strain 
(Chumakov et al, 1961) 
 
Mass vaccinations since 1959 with 
contaminated Russian vaccine (OPV). A 
small proportion of persons were 
vaccinated with IPV at the beginning of 
the mass vaccinations (Chumakov et al, 
1961; Chumakov et al, 1963; Shah & 
Nathanson , 1976; Levine et al, 
1998;Chron Wld Hlth Org 1960). 
 
Mass vaccinations since 1963 with British 
vaccine (OPV) [101]; British vaccines 
were SV40-free since 1962 (Sangar et al, 
1999); in contrast some vaccines were 
later claimed to have been contaminated 
(De Sanjose et al, 2003). 
 
In 1957 potentially contaminated U.S. 
vaccine (IPV), from 1958 SV40-free 
Swedish vaccine (IPV). Sweden has 
never used OPV (Murdin et al, 1996) 
 
Vaccination was not started before 1970, 
at a time where polio vaccines were 
required to be SV40-free (De Rienzo et al, 
2002). The type of the vaccine is unclear. 
In a global poliomyelitis eradication 
initiative starting in 1989, OPV was used. 
 
Vaccination started in 1956 with OPV 
(Chron Wld Hlth Org, 1958; Chron Wld 
Hlth Org, 1960). SV40-free since 1962 
(Rev Sanid Hi Publica, 1965) 
 
Table 1. (Leithner, 2005) 
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We were aimed at carrying out epidemiological investigation and determining infection of 
population with polyomavirus SV40 in different regions of Russia and also determine 
intensity and source of infection. Investigation was carried out mainly anonymously. Each 
sample was accompanied with information about the place from where the sample was 
delivered, sex and age of the person.  
To determine SV40 infection of population in Russia we decided to determine virus DNA 
sequences in blood samples of persons of different sex and age delivered to us by different 
medical institutions from different regions of Russia. Investigation of biological samples for 
SV40 is rather difficult because standard PCR and immunological tests (IFA, western 
blotting) do not allow differentiation of SV40 from widely spread ubiquitous human 
polyomaviruses JCV and BKV which have cross-immunological and cross molecular-
biological-reactivity with SV40 (Viscidi, 2003). That is why for SV40 detection we chose the 
recommended method Real Time PCR (RQ-PCR) with TaqMan probe addressed to the area 
with 9-nucleotid deletion distinguishing SV40 from JVC and BKV.  
2. Methods 
For PCR analysis 100 ul of blood was put into a test tube containing EDTA and kept at 4o C 
until it was delivered to the laboratory for DNA extraction. After extraction DNA samples 
were kept at -20o C. 
Genome of SV40 can be present in the cell in 2 forms: episomal or integrated into genome of 
host cell. Because of few SV40 copies in the sample the best method allowing detecting 
episomal forms of SV40 DNA in RQ-PCR are methods based on DNA sorption by SiO2. That 
is why we used modified GuSCN protocol (Boom et al., 1992, Testa et al., 1998) for 
extraction of DNA from whole blood. 
Three hundreds microliters of solution containing 5 M GuSCN,1% Triton X-100(v/v), 20 
mM EDTA, 50 mM Tris-HCl (pH 6,4), 10 ul SiO2 was added to the blood sample (100 ul) and 
incubated 15 min, centrifugated and the sediment was washed once in 5 M GuSCN, 50 mM 
Tris-HCl (pH 6,4) and twice in 10 mM Tris-HCl (pH 7,3), 50 mM NaCl, 50% ethanol. The 
sample was desiccated in thermostat and DNA was eluted by TE-buffer (10 mM Tris-HCl 
(pH 8,0), 1Mm EDTA). For PCR amplification 5 ul were used. Rest was kept at -20o C. 
As it was mentioned above SV40 detection was carried out by RQ-PCR method with 
internal probe directed to SV40 genome region in 4517 position, characterized by deletion of 
9 nucleotides distinguishing SV40 from viruses JCV and BKV. PCR was carried out on 
BioRad Thermocycler according to the following program: 5 min initial denaturation, then 8 
sec at 94oC, 23 sec at 60oC, 30 sec at 72oC, during 50 cycles. DNA extracted from M.mulatta 
blood was used as positive control. Water 5 ul from opened test tube kept together with 
extracted DNA samples was used as negative control.  
3. Results 
In total 768 blood samples obtained from different cities and regions of Russian Federation 
(St. Petersburg - 56, Moscow – 50, Krasnodar region – 352, Novosibirsk – 108, Krasnoyarsk 
region – 202) have been investigated by RQ-PCR. Results of these investigations are 
presented in Table 2.   
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Region 
Number of 
samples 
Number of SV40 positive 
Absolute 
number 
% 
Krasnodar region 
Moscow 
St. Petersburg 
Novosibirsk 
Krasnoyarsk region 
100 
50 
56 
108 
202 
49 
8 
8 
32 
64 
49 
16 
14 
29.6 
26.7 
Table 2. 
Because this investigation revealed a rather high number of SV40 carriers in Krasnodar 
region we decided to check the situation in Sochi and Adler (Table 3). 
 
Region 
Number of 
samples 
Number of SV40 positive 
Absolute  number % 
Sochi 102 44 43 
Adler 150 48 32 
Table 3. 
To confirm the results of RQ PCR, and prepare amplicons for sequencing another sets 
(SV5/SV6) of primers directed to conservative region 173-bp length of SV40 T-ag were used. 
These PCR primers amplify a region of SV40 that could be distinguished from BK and JC 
viral DNA. (Testa et al. 1998).  
 
Fig. 2. 
The ethidium bromide-stained 2.5% agarose gel shows the PCR products of 9 blood 
samples, some of which are SV40 positive. N10(-) control (water), 11 (+) control (DNA 
extracted from blood of SV40+ positive M. mulatta). 
The obtained samples were sequenced on a ABI Prism 377 sequenator. Result of sequencing 
confirmed belonging of amplified regions to SV40. 
We believe that the results can be corrected both towards the increase and towards 
reduction on the basis of age, sex and other factor analyzes of representative groups. 
Nevertheless obtained material allows drawing some conclusions. High percent of SV40 
infected children in Sochi and Krasnodar region at the age of 10 years who were immunized 
with poliovaccine reliably free from contamination with this virus definitely testifies 
horizontal way of contamination. 
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Numerous publications are devoted to polyomavirus problem and a great part of them to 
SV40 problem: reliability or unauthenticity of SV40 detection in healthy people, in human 
neoplasm, SV40 role in tumor emergence, SV40 origin and ways of spreading are  discussed. 
In a great degree a lot of publications are connected with scandalous character of the 
problem – SV40 introduction into human population during immunization against 
poliomyelitis.  
Despite the fact that preparing vaccines on rhesus kidney cell cultures was stopped about  
30 years ago SV40 carrying is still determined in high percent of cases in healthy  
persons and also in some malignant human neoplasm (brain tumors, mesotheliomas, 
osteosarcomas etc.). 
Polyomavirus SV40 has been detected practically on all continents (Fig. 2). After 
introduction it into human population it should be considered as human virus – man has 
become its reservoir. The virus circulates among people, spreading horizontally, excretes 
into surrounding, pollutes it and this is perhaps a very important factor of its 
epidemiology.  
 
Fig. 3. SV40 infection of population was discovered on all Continents. Black color designates 
countries where SV40 carriers were discovered. However it does not mean the prevalence of 
SV40 infection. 
4. Сonclusion 
In this article data on analysis of SV40 polyomavirus contamination of population in some 
regions of Russia are presented. Infection was detected by PCR in real time (RQ-PCR) with 
TaqMan probe directed to the site of 9 nucleotide deletion distinguishing SV40 from 
ubiquitous human viruses JCV and BKV, The source of infection was mainly vaccination 
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with Sabin OPV vaccine contaminated with SV40. Virus SV40 was detected in archive 
vaccine samples produced in East European countries before 1978 because heating with 
MgCl2 did not free the vaccine from SV40 contamination. Infection rate was investigated in 5 
Russian regions: Russia (Moscow, St. Petersburg, cities of the Black Sea coast, Novosibirsk 
and Krasnoyarsk region).  
The highest values were detected on the Black Sea and the lowest in St. Petersburg. Presence 
of SV40 in children vaccinated with reliably decontaminated vaccine confirms possibility of 
horizontal spreading of the virus. According to reference data contamination of population 
was revealed on all Continents.    
Despite the fact that preparing polio vaccine on culture of M.mulatta kidney cells was 
stopped 30 years ago SV40 carriage still exists in healthy people in rather high percent and 
also in human malignant neoplasms practically in all countries, on all Continents (Basetse, 
2002; Leithner et al., 2006; Minor et al., 2003; Zekri et al., 2007; Dang-Tan et al., 2004). 
Polyomavirus SV40 was introduced into human population and should be considered as 
human virus. Man has become its reservoir. The virus circulates among people, spreads 
horizontally, excretes into environment and pollutes it and this is an important factor in its 
epidemiology.    
Perhaps true value of SV40 prevalence in different regions can be established at examination 
of randomized groups generated on age, sex, place of residing, conditions of life and 
cultural skills. 
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